4.50
+0.23(+5.39%)
Currency In USD
| Previous Close | 4.27 |
| Open | 4.35 |
| Day High | 4.56 |
| Day Low | 4.15 |
| 52-Week High | 6.33 |
| 52-Week Low | 2.01 |
| Volume | 4.7M |
| Average Volume | 5.49M |
| Market Cap | 672.85M |
| PE | -4.74 |
| EPS | -0.95 |
| Moving Average 50 Days | 3.17 |
| Moving Average 200 Days | 3.17 |
| Change | 0.23 |
If you invested $1000 in Absci Corporation (ABSI) since IPO date, it would be worth $208.43 as of October 28, 2025 at a share price of $4.5. Whereas If you bought $1000 worth of Absci Corporation (ABSI) shares 3 years ago, it would be worth $1,397.52 as of October 28, 2025 at a share price of $4.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial
GlobeNewswire Inc.
Oct 15, 2025 12:00 PM GMT
Webinar on December 11 to feature leading KOLs in dermatology and hair loss alongside Absci leadership Phase 1/2a trial now expected to begin in December 2025, ahead of prior guidance VANCOUVER, Wash. and NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -
Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD
GlobeNewswire Inc.
Sep 11, 2025 12:00 PM GMT
Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costsAUSTIN, Texas and VANCOUVER, Washington, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Absci, a clinical-stage bio
Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg
GlobeNewswire Inc.
Aug 25, 2025 8:05 PM GMT
World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia.VANCOUVER, Wash. and NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI),